化疗不良反应的对症护理对复发转移乳腺癌患者生活质量的影响

目的 研究针对化疗不良反应的对症护理对复发转移乳腺癌患者生活质量的影响.方法 选取本科2015年1~7月96例复发转移乳腺癌患者为研究对象,将患者随机分为观察组和对照组,每组48例,对观察组采用针对化疗不良反应的对症护理,对照组采用常规护理,比较两组护理3个月后的生活质量(躯体、角色、认知、情绪、社会和总体健康状况)、焦虑症状和不良反应发生率.结果 观察组护理3个月后的总体健康状况得分为(80.52±23.12)分显著高于对照组的(71.43±18.43)分(P<0.05).观察组的焦虑发生率、不良反应发生率分别为16.7%、12.5%显著低于对照组的39.6%、31.3%(P<0.05).结论 针对化疗不良反应的对症护理可以减少复发转移乳腺癌患者化疗过程中的毒副作用对患者的损伤,缓解患者的紧张焦虑情绪,改善患者的生活质量,值得临床应用和推广.

The influence of the countermeasures targeted at adverse reaction of chemotherapy on the quality of life of the patients with metastatic breast cancer

Objective To study the influence of the countermeasures targeted at adverse reaction of chemo-therapy on the quality of life of the patients with metastatic breast cancer. Methods A total of 96 cases of patients with recurrent and metastatic breast cancer treated in our hospital from January to July 2015 were selected as the study ob-jects. They were randomly divided into observation group and control group, 48 cases of each group. Patients in the obser-vation group were given symptomatic nursing targeted at adverse reaction of chemotherapy, while patients in the control group were given conventional nursing. The quality of life ( including body condition, character, cognition, society and general health condition ) , the occurrence rate of anxiety symptom and adverse reaction of the two groups 3 months after nursing were compared. Results Three months after nursing, the general health condition scores of the observation group were (80. 52 ± 23. 12 ) scores which were obviously higher than that of the control group ( 71. 43 ± 18. 43 ) scores ( P<0. 05). The anxiety symptom rate and adverse reaction occurrence rate of the observation group were 16. 7% and 12. 5%respectively, which were obviously lower than the control group's 39. 6% and 31. 3% (P<0. 05) . Conclusion Symp-tomatic nursing targeted at adverse reaction of chemotherapy can reduce the toxic and side effect, relieve the anxiety and improve the patients' quality of life. Thus, it deserves to be applied and promoted in the clinical field.